期刊文献+

四株人白血病多药耐药细胞系的建立及其生物学特性的初步研究 被引量:2

A PRELIMINARY STUDY ON ESTABLISHMENT AND CHARACTERIZATION OF FOUR HUMAN MULTIDRUGRESISTANT LEUKEMIC CELL LINES
暂未订购
导出
摘要 我们对人红白血病细胞株K562和人早幼粒细胞白血病细胞株HL-60应用高三尖杉酯破(HHT)或长春新碱(VCR),采用反复短期暴露法,并逐渐增加HHT和VCR的浓度,成功地建立了K562/VCR、K562/HHT、HL-60/VCR和HL-60/HHT四株具有高度耐药性的多药耐药(MDR)细胞系。免疫组织化学染色显示,K562/VCR、K562/HHT及HL60/VCR三株MDR细胞系有卜糖蛋白(Pgp)的高度表达,而HL-60/HHT细胞系没有pgP的表达。四株MDR细胞系均未见有多药耐药相关蛋白(MRP)的表达。5μg/ml异搏定和50μg/ml红霉素都能部分逆转K562/VCR、K562/HHT和HL-60/VCR三株MDR细胞系的耐药性,但其对HL-60/HHT细胞系的耐药性几乎无逆转作用。四株MDR细胞系与其相应敏感细胞系相比,前者对DNR的摄取均减少,外排均增加。2.5~10μg/ml异搏定能增加K562/VCR、K562/HHT和HL-60/VCR三株MDR细胞系对DNR的摄取量和滞留量,且其作用随异搏定浓度的增加而增强,但50~200μgn/ml红霉素不能增加它们对DNR的摄取量和滞留量。上述浓度异搏定或红霉素均不能增加HL-60/HHT细胞系对DNR的摄取量和滞留量。 We established four human highly multidrug- resistant (MDR ) leukemic cell lines (K562/VCR, K562/HHT, HK-60/VCR and HL-60/HHT) from human erythroleukemiacell line K562 and human promyelocytic leukemia cell line HL-60 by short and exposures to HHT or VCR with gradually increasing concentration of HHT or VDR. Immunohistochemical staining demonstrated K562/VCR, K562/HHT and HL-60/VCR MDR cell lines overexpressed p-glycoprotein (Pgp), but HL-60/HHT cell line didn' t. No expression of MDR-related protein (MRP) was found in all four MDR cell lines. The resistance of K562/VCR or K562/HHT or HL-60/VCR MDR cell line could be partly reversed, hut that of HL-60/HHT MDR cell line could be hardly done by 5μg/ml verapamil or 50μg/ml erythromycin.Both DNR accumulation reduced and DNR efflux increased in four MDR cell lines as compared with their parental cell lines. 2. 5~10μg/ml verapamil was able to increase DNR accumulation and retention in K562/VCR, K562/HHT and HL-60/VCR MDR cell lines, and the more verapamil, the more DNR accumulation and retention, but not in HL-60/HHT MDR cell line. 50-200μg/ml erythromycin was unable to increase NDR accumulation and retention on four MDR cell lines.
出处 《中国小儿血液》 1997年第5期193-197,203,共6页 China Child Blood
  • 相关文献

参考文献4

二级参考文献6

  • 1Qian X D,Cancer Res,1990年,50卷,1132页
  • 2Ling V,Cancer,1992年,69卷,2603页
  • 3Robert T. Dorr,James D. Liddil. Modulation of mitomycin C-induced multidrug resistance in vitro[J] 1991,Cancer Chemotherapy and Pharmacology(4):290~294
  • 4Takashi Tsuruo,Mikihiko Naito,Riko Takamori,Satomi Tsukahara,Junko Yamabe-Mitsuhashi,Akiko Yamazaki,Tomoko Oh-hara,Yojiro Sudo,Shiro Nakaike,Takehiro Yamagishi. A benzophenazine derivative,N-β-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide, as a new antitumor agent against multidrug-resistant and sensitive tumors[J] 1990,Cancer Chemotherapy and Pharmacology(2):83~87
  • 5Tomoko Yoshinari,Yoshikazu Iwasawa,Keiko Miura,Ikuko S. Takahashi,Takahiro Fukuroda,Kunio Suzuki,Akira Okura. Reversal of multidrug resistance by new dihydropyridines with lower calcium antagonistic activity[J] 1989,Cancer Chemotherapy and Pharmacology(6):367~370
  • 6Bharathi Vayuvegula,Lewis Slater,Josephine Meador,Sudhir Gupta. Correction of altered plasma membrane potentials[J] 1988,Cancer Chemotherapy and Pharmacology(2):163~168

共引文献22

同被引文献22

  • 1汪清,辛殿祺,丁义,郭应禄.茶多酚诱导EJ膀胱肿瘤细胞凋亡并增加化疗药物吡柔比星的抗肿瘤协同作用[J].中华实验外科杂志,2005,22(1):12-14. 被引量:5
  • 2雷瑚仪,赵谢兰.NF-κB活化及WT1、MDR1的表达在急性非淋巴细胞白血病中的临床意义[J].中国实验血液学杂志,2007,15(2):253-257. 被引量:9
  • 3Del-Poeta G,Venditti A,Del-Principe MI,et al.Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)[J].Blood,2003;101(6):2125-31.
  • 4Han Z,Hong L,Han Y,et al.Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp,Bcl-2 and Bax[J].J Exp Clin Cancer Res,2007;26(2):261-8.
  • 5Mei Y,Qian F,Wei D,et al.Reversal of cancer multidrug resistance by green tea polyphenols[J].J Pharm Pharmacol,2004;56(10):1307-14.
  • 6Huang Y,Ibrado AM,Reed JC,et al.Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells[J].Leukemia,1997;11(2):253-7.
  • 7Yang CS,Chung JY,Yang G.Tea and tea polyphenols in cancer prevention[J].J Natr,2000;130(2):472-8.
  • 8Picot J, Cooper K, Bryant J, et al. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first- line treatment of multiple myeloma: a systematic review and eco- nomic evaluation. Health Technol Assess, 2011, 15:201-204.
  • 9Li ZW, Chen H, Campbeil RA, et al. NF-kappaB in the patho- genesis and treatment of multiple myeloma. Curr Opin Hematol, 2008, 15:391-399.
  • 10Kane RC, Dagher R, Fan'ell A, et al. Bortezomib for the treat- ment of mantle cell lymphoma. Clin Cancer Res, 2007, 13:5291- 5294.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部